Zhejiang Conba Pharmaceutical’s Inhalable Pirfenidone for IPF Clears for Chinese Clinical Trials
Zhejiang Conba Pharmaceutical Co., Ltd (SHA: 600572) has announced that its modified version of US...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Two Autoimmune Disease Drug Candidates
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has separately announced clinical trial approvals from the National...
Sino-US Laekna Receives FDA Clearance for LAE102 Clinical Trial in NSCLC
Sino-US Laekna has announced that it has received clinical trial clearance from the US Food...
Beijing Hospitals to Pilot DRG-VBP Reforms for Medical Consumables Procurement
The Beijing Municipal Medical Insurance Bureau has released a notification indicating that six hospitals in...
Lundbeck A/S Reports Record Quarterly Revenue in Q1 2023 with 11% YOY Increase
Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) has released its financial report for the first...
Cabaletta Bio’s CABA-201 Clears FDA for Phase I/II Study in Idiopathic Inflammatory Myopathy
US-based Cabaletta Bio, Inc. (NASDAQ: CABA) has announced that the US Food and Drug Administration...
MicroPort Scientific Plans IPO for Subsidiary MicroPort CRM on Hong Kong Stock Exchange
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced its intention to spin...
Mustang Bio, Inc. Enters Strategic Partnership with uBriGene for Cell and Gene Therapy
US-based Mustang Bio, Inc. has announced a strategic partnership with uBriGene (Boston) Biosciences Inc., the...
Beijing Sun-Novo Secures Exclusive Rights to Kaneka’s Skin Patch Drugs in Licensing Deal
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a licensing agreement with...
International Vaccine Institute and Nankai University Establish Joint Research Center for Vaccine Advancements
The International Vaccine Institute (IVI), a non-profit international organization initiated by the United Nations Development...
MicroPort MedBot Receives NMPA Approval for Mona Lisa Prostate Puncture Robot System
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing...
Liaoning-Led Alliance Launches Volume-Based Procurement Tender for Hernia and Dural Patches
A 12-strong provincial procurement alliance, spearheaded by Liaoning province, has announced the initiation of a...
Asieris Pharmaceuticals Secures Exclusive Global Rights to UroViu’s Fluorescent Imaging Cystoscope
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced a strategic collaboration with US...
Abbisko Therapeutics and X4 Pharmaceuticals Announce Positive Phase III Results for Mavorixafor in WHIM Syndrome
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) and its US partner X4 Pharmaceuticals Inc....
Shenzhen Kangtai Biological Partners with Saudi Importer for Pneumonia Vaccine Distribution
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced a strategic partnership with...
FibroGen’s Roxadustat Shows Positive Results in Phase III Chemotherapy-Induced Anemia Trial
US-based FibroGen Inc. (NASDAQ: FGEN) has announced positive topline data from a Phase III trial...
GenScipt Biotech Corp. Expands Oligonucleotide and Peptide Manufacturing in Zhenjiang
China-based Contract Development and Manufacturing Organization (CDMO) GenScipt Biotech Corp. (HKG: 1548) has revealed the...
NMPA Approves Nanjing Sanhome’s Alfosbuvir for Chronic Hepatitis C Treatment
Nanjing Sanhome Pharmaceutical Co., Ltd has announced that its Category 1 drug alfosbuvir has been...
Betta Pharmaceuticals Initiates Phase I/II Study for First-In-Class BsAb BPB-101
China’s Betta Pharmaceuticals (SHE: 300558) has announced the enrollment of the first patient in a...
Antengene’s First-in-Class CD24 mAb ATG-031 Gets US FDA Approval for Phase I Study
Antengene Corp., Ltd (HKG: 6996) has announced that it has received approval from the US...